Tag Archives: Avastin

Avastin Users Wanted for New Research Study

Fight Colorectal Cancer is partnering together with 23andme and Genentech to help researchers better understand if patients’ genes play a role in how they respond to treatments they receive for their colorectal cancer.  This provides patients a new opportunity to participate in genetics research. You are invited to participate in the InVite Study. The InVite Study aims to enroll 1,000 individuals with certain types of advanced cancer who received Avastin before 2013. In order to participate you simply submit a saliva sample and complete some online surveys. The InVite Study will allow you to: Learn more about your health and genetic ancestry Take a direct role in research that may

FDA Approves Avastin for New Second-Line Use

For patients with metastatic colorectal cancer, the Food and Drug Administration (FDA) has approved a new use of Avastin® (bevacizumab): It can be continued as part of ‘second-line’ combination therapy, even if it was used in first-line therapy. When stage IV cancer progresses despite use of Avastin plus either FOLFOX (5FU plus Eloxatin® or oxalyplatin) or FOLFIRI (5FU plus Camptosar® or irinotecan)-based chemotherapy, the FDA has now approved continued use of Avastin when second-line treatment switches to the other chemotherapy. Avastin is a monoclonal antibody (a “targeted drug”) that helps prevent a cancer from stimulating growth of new blood-vessels that then help the tumor get bigger. The FDA’s approval is based on a large, randomized

Memorial Sloan-Kettering Will Not Offer Zaltrap

Memorial Sloan-Kettering Cancer Center made a very public announcement—and explanation—today in a New York Times op-ed about why they will not offer the new drug Zaltrap® (ziv-aflibercept) to its metastatic colorectal cancer patients. The authors, all world-renowned cancer specialists at the world’s oldest cancer center, in an op-ed headlined “In Cancer Care, Cost Matters,” essentially challenged other cancer centers to take action where politicians fear to tread. “We recently made a decision that should have been a no-brainer,” wrote Drs. Peter B. Bach, Leonard B. Saltz and Robert E. Wittes. “The drug, Zaltrap, has proved to be no better than a similar medicine we already have for advanced colorectal cancer, while its price—at

Avastin Second-Line Treatment Improves Survival Time

Continuing Avastin into second-line chemotherapy for advanced colorectal cancer when tumors begin to grow larger or new tumors appear (progression) improves both survival time and the time until further progression according to Phase III clinical trial results that will be reported this Sunday morning, June 3, at ASCO 2012 in Chicago Study results were previewed in an ASCO Press Briefing yesterday. Overall survival time increased by 19% with Avastin compared to a switch to a new chemotherapy alone. Time until cancer progressed fell 32%. Serious side effects remained similar.

Fake Avastin Discovered in US

The Food and Drug Adminstration and Genentech have reported that counterfeit Avastin is being distributed in the United States. The counterfeit medicine does not contain bevacizumab, Avastin’s active ingredient. The packaging is different from genuine Avastin marketed here by Genentech. It includes a Roche logo which isn’t on the real drug, along with different codes. Avastin is not in shortage now, and there are adequate supplies to meet the need. Patients being treated with Avastin are urged to let their doctors know immediately if they have unusual symptoms.

Avastin with XELIRI or FOLFIRI: Is There Any Difference?

When Avastin is added to the combination of Xeloda and irinotecan as an initial treatment for advanced colorectal cancer, the treatment is equally effective as Avastin with FOLFIRI. But side effects are more difficult. After a randomized clinical trial comparing Avastin with XELIRI (Xeloda, irinotecan) to Avastin with FOLFIRI (5-FU, leucovorin, irinotecan), researchers concluded that excessive side effects made using the XELIRI combination unwise.

FDA Avastin Breast Cancer Decision Doesn’t Impact Colorectal Cancer Treatment

Although FDA Commissioner Margaret Hamburg announced a final decision on November 18 to drop breast cancer from the Avastin label, metastatic colorectal cancer continues to be an approved use. The Avastin® (bevacizumab) label includes the following approved indication: Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment. It is important to know that there is currently no approval or evidence for using Avastin alone or in early stage colon or rectal cancer.

FDA Avastin Breast Cancer Decision Doesn't Impact Colorectal Cancer Treatment

Although FDA Commissioner Margaret Hamburg announced a final decision on November 18 to drop breast cancer from the Avastin label, metastatic colorectal cancer continues to be an approved use. The Avastin® (bevacizumab) label includes the following approved indication: Metastatic colorectal cancer, with intravenous 5-fluorouracil–based chemotherapy for first- or second-line treatment. It is important to know that there is currently no approval or evidence for using Avastin alone or in early stage colon or rectal cancer.

FDA: Avastin Can Cause Ovarian Failure

The FDA has changed the package insert for Avastin® (bevacizumab) to include information about newly identified risks for the drug including Loss of ovarian function (ovarian failure). Bone death in the jaw (osteonecrosis). Bleeding and additional blood clots in patients who have already had a clot in their veins while on Avastin. Changes to the Avastin label were announced on September 30, 2011.

Avastin Still Approved for Advanced Colorectal Cancer

Yesterday’s recommendation by the FDA’s Oncology Drug Advisory Committee (ODAC) that approval of Avastin for breast cancer be withdrawn will not affect colorectal cancer treatment. Avastin® (bevacizumab) remains on the market in the US and is FDA-approved  for advanced colon and rectal cancer in combination with chemotherapy, both as first-line and second-line therapy. The public hearing held on June 28 and 29 reviewed the process began  in December, 2010 to withdraw the FDA provisional approval of Avastin for metastatic, HER-2 negative breast cancer.  It did not consider or change other label indications for colorectal, kidney, or small cell lung cancers or glioblastoma. A final decision on breast cancer will be

Top